Skip to main content
CDC Website

Resources Access for Preclinical Integrated Drug Development (RAPIDD) Program (X01 Clinical Trial Not Allowed)

The purpose of this FOA is to provide a method for investigators to request gap filling preclinical services to academic and private institutions to assist with product development efforts and facilitate the advancement of promising therapeutics for HIV and HIV-associated co-infections (Hepatitis B, Hepatitis C and Tuberculosis).

Funding Organization:
US Department of Health and Human Services National Institutes of Health
Funding Category:
HIV/AIDS
Support Types:
Discretionary Grants
Locations:
National
Fund Number:
364791
Fund ID:
PAR-22-185
Application Due Date:
Subjects:
HIV
HIV and AIDS Prevention
Audiences:
Persons with HIV/AIDS
Last Updated:
Application Contact
Betty
Poon
In Vitro Testing and Screening of HIV compounds
240.669.5024
poonb@niaid.nih.gov
Technical Contact
Brigitte
Sanders
Evaluations in Small Animal Models for HIV, HBV, HCV and MTB
240.627.3209
sandersbe@niaid.nih.gov